Efficacy of thoracotomy and thoracoscopic-assisted esophageal surgery in conversion and salvage surgeries: a retrospective study.
Chemoradiotherapy
Chemotherapy
Conversion surgery
Esophageal cancer
Salvage therapy
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
23 May 2022
23 May 2022
Historique:
received:
20
09
2021
accepted:
09
05
2022
entrez:
22
5
2022
pubmed:
23
5
2022
medline:
25
5
2022
Statut:
epublish
Résumé
The esophagus has no serosa; therefore, esophageal cancer may quickly invade its adjacent organs. In recent years, reports of conversion surgery (CS) and salvage surgery (SS) have described resection of esophageal cancer previously considered unresectable, with the addition of intensive preoperative chemotherapy or chemoradiotherapy. Currently, there is no established method for determining whether tumor excision is possible. Additionally, differences in surgical approaches between facilities may influence outcome after resection. However, the option for resection is considered a significant factor in determining a patient's prognosis. Patients who were diagnosed with advanced-stage (T3 or higher) squamous cell carcinoma of the esophagus and subsequently underwent resection with CS or SS were included in the study. Resection was performed through a small thoracotomy using a thoracoscope. Clinicopathologic factors, such as complete resection rate (R0) and prognosis, were investigated. A total of 49 surgeries were conducted: 39 CS and 10 SS cases. The male-to-female ratio was 37:12. R0:R1:R2 equals 42:3:4, and the R0 resection rate was 85.7%. The 5-year survival rates for CS and SS cases were 69.2% and 32.1%, respectively. The 5-year survival rates for R0, R1, and R2 resections were 63.4%, 0.0%, and 25.0%, and those for R0 and R1 + 2 resections were 63.4% and 14.3%, respectively, indicating that the prognosis for R0 resection cases was significantly better (P = 0.001 and P = 0.001, respectively). Regarding chemotherapy for CS, 29 patients received 5-FU and cisplatin therapy, whereas 10 patients received 5-FU, cisplatin, and docetaxel (DCF) therapy. After 2015, the ratio of DCF was significantly high, and the R0 resection rate was 100% in patients who received DCF therapy. In this study, a satisfactory R0 rate was achieved using the magnifying effect of the thoracoscope while ensuring safety during thoracotomy. This was a single-center cohort study wherein clinical data were retrospectively registered. This study was approved by the Chiba Cancer Center review board (H29-262). All procedures adhered to the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration of 1964 and its later amendments.
Sections du résumé
BACKGROUND
BACKGROUND
The esophagus has no serosa; therefore, esophageal cancer may quickly invade its adjacent organs. In recent years, reports of conversion surgery (CS) and salvage surgery (SS) have described resection of esophageal cancer previously considered unresectable, with the addition of intensive preoperative chemotherapy or chemoradiotherapy. Currently, there is no established method for determining whether tumor excision is possible. Additionally, differences in surgical approaches between facilities may influence outcome after resection. However, the option for resection is considered a significant factor in determining a patient's prognosis.
METHODS
METHODS
Patients who were diagnosed with advanced-stage (T3 or higher) squamous cell carcinoma of the esophagus and subsequently underwent resection with CS or SS were included in the study. Resection was performed through a small thoracotomy using a thoracoscope. Clinicopathologic factors, such as complete resection rate (R0) and prognosis, were investigated.
RESULTS
RESULTS
A total of 49 surgeries were conducted: 39 CS and 10 SS cases. The male-to-female ratio was 37:12. R0:R1:R2 equals 42:3:4, and the R0 resection rate was 85.7%. The 5-year survival rates for CS and SS cases were 69.2% and 32.1%, respectively. The 5-year survival rates for R0, R1, and R2 resections were 63.4%, 0.0%, and 25.0%, and those for R0 and R1 + 2 resections were 63.4% and 14.3%, respectively, indicating that the prognosis for R0 resection cases was significantly better (P = 0.001 and P = 0.001, respectively). Regarding chemotherapy for CS, 29 patients received 5-FU and cisplatin therapy, whereas 10 patients received 5-FU, cisplatin, and docetaxel (DCF) therapy. After 2015, the ratio of DCF was significantly high, and the R0 resection rate was 100% in patients who received DCF therapy.
CONCLUSIONS
CONCLUSIONS
In this study, a satisfactory R0 rate was achieved using the magnifying effect of the thoracoscope while ensuring safety during thoracotomy.
TRIAL REGISTRATION
BACKGROUND
This was a single-center cohort study wherein clinical data were retrospectively registered. This study was approved by the Chiba Cancer Center review board (H29-262). All procedures adhered to the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration of 1964 and its later amendments.
Identifiants
pubmed: 35599328
doi: 10.1186/s12957-022-02637-8
pii: 10.1186/s12957-022-02637-8
pmc: PMC9125810
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
163Informations de copyright
© 2022. The Author(s).
Références
Ann Surg. 2021 Dec 1;274(6):e465-e472
pubmed: 33065643
Asian J Endosc Surg. 2020 Apr;13(2):152-159
pubmed: 31313511
Ann Surg Oncol. 2020 Feb;27(2):460-467
pubmed: 31376034
J Surg Oncol. 2009 Nov 1;100(6):442-6
pubmed: 19653262
Anticancer Res. 2019 Jun;39(6):3167-3175
pubmed: 31177163
World J Surg. 2019 Aug;43(8):2006-2015
pubmed: 30972432
Esophagus. 2020 Jan;17(1):59-66
pubmed: 31595397
Ann Surg Oncol. 2019 Aug;26(8):2580-2586
pubmed: 31144141
J Thorac Cardiovasc Surg. 2009 Jan;137(1):49-54
pubmed: 19154902
Anticancer Res. 2011 Oct;31(10):3535-41
pubmed: 21965775
Esophagus. 2017;14(4):324-332
pubmed: 28983229
Ann Surg Oncol. 2015 Dec;22(13):4438-44
pubmed: 25862582
Br J Cancer. 2016 Nov 22;115(11):1328-1334
pubmed: 27811857
Gen Thorac Cardiovasc Surg. 2007 Nov;55(11):461-4; discussion 464-5
pubmed: 18049854
Biomed Res Int. 2018 May 20;2018:8591387
pubmed: 29888281
J Gastroenterol. 2011 Nov;46(11):1284-91
pubmed: 21818602
N Engl J Med. 2015 Apr 9;372(15):1472-3
pubmed: 25853757
Ann Surg Oncol. 2021 Feb;28(2):712-721
pubmed: 32761331
World J Surg. 2010 Feb;34(2):277-84
pubmed: 20033687
Esophagus. 2019 Jul;16(3):221-245
pubmed: 31098822
Ann Surg. 2020 Jul;272(1):118-124
pubmed: 30720501
Dis Esophagus. 2018 Apr 1;31(4):
pubmed: 29190316
Ann Surg Oncol. 2019 Dec;26(13):4737-4743
pubmed: 31414291
N Engl J Med. 2014 Dec 25;371(26):2499-509
pubmed: 25539106